Microbot Medical Inc. announced on June 9, 2025, an update regarding the anticipated U.S. launch of its LIBERTY Endovascular Robotic System. The company now expects the U.S. Food and Drug Administration (FDA) 510(k) decision during the third quarter of 2025, a shift from the previous Q2 2025 expectation.
The company clarified that this updated FDA decision timeline remains within the FDA’s original scheduled review window and is not expected to affect the planned launch upon clearance, which is also projected for Q3 2025. Microbot Medical remains actively engaged with the FDA.
As part of its ongoing launch preparation, Microbot Medical expanded its commercial team with the addition of Michael Lytle as the head of Sales Operations & Analytics. Mr. Lytle brings deep experience in sales support and data analysis, which is expected to optimize the sales cycle and drive strategic growth for the LIBERTY system.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.